What biomarker testing is recommended for early stage Ovarian Cancer

Biomarker Testing for Early-Stage Ovarian Cancer

I'll walk you through what the current medical guidelines recommend for biomarker testing in early-stage ovarian cancer, and importantly, what the evidence shows about their limitations.

The Primary Biomarker: CA-125

CA-125 is the most established biomarker for ovarian cancer. According to NCCN Guidelines, CA-125 testing can be useful in early-stage disease for several reasons:

• Prognostic value: Elevated pretreatment CA-125 levels correlate with the extent of disease and can help with treatment planning
• Monitoring response: CA-125 levels tend to track with how well treatment is working, especially in patients who had elevated levels before treatment
• Surveillance: It can help detect recurrence after treatment, particularly in patients whose CA-125 was elevated at diagnosis

However, it's important to understand that CA-125 alone is not specific to ovarian cancer — it can be elevated in benign conditions and other cancers, so it must be interpreted in the full clinical context.

Other Biomarkers to Consider

According to NCCN Guidelines, additional tumor markers may be tested depending on the specific situation:

• HE4 (Human Epididymis Protein 4): Some evidence suggests HE4 may be useful as a prognostic marker and for detecting recurrence, particularly in patients without elevated CA-125. However, the guidelines note that results vary across studies, so routine HE4 testing is not currently recommended as standard practice.

• Specialty markers (depending on tumor type):

  • AFP, beta-hCG, and LDH: For germ cell tumors (a less common ovarian cancer type)
  • Inhibin: For granulosa cell tumors (a sex cord-stromal tumor type)
  • CA19-9 and CEA: May be measured if clinically indicated

What the Evidence Shows About Multi-Marker Tests

The NCCN Guidelines specifically address multi-biomarker assays (tests combining multiple markers). Here's what's important to know:

Current recommendation: The NCCN Panel does not recommend using multi-biomarker tests for determining whether an undiagnosed pelvic mass is cancer. These tests are designed only for preoperative assessment in patients who already have a known mass and are planning surgery — not for screening or early detection in asymptomatic women.

The guidelines note that "not all studies have found that multi-biomarker assays improve all metrics (sensitivity, specificity, predictive value) compared with other methods like imaging or clinical assessment."

Important Limitations for Early Detection

According to NCCN Guidelines, research shows that several markers — including CA-125, HE4, mesothelin, B7-H4, and others — do not increase early enough to be useful in detecting early-stage ovarian cancer. This is a critical point: these biomarkers are better for monitoring known disease than for catching cancer at its earliest stages.

Molecular Testing Recommendations

Beyond traditional biomarkers, NCCN Guidelines recommend molecular testing (genetic testing) for all patients with confirmed ovarian cancer:

• BRCA1/2 testing (germline and somatic): Critical because it determines eligibility for PARP inhibitor maintenance therapy
• Homologous recombination status (HRD): Helps predict benefit from PARP inhibitors even without a BRCA mutation
• This testing should be done as part of initial workup to inform treatment decisions

Questions to Ask Your Healthcare Team

If you've been diagnosed with early-stage ovarian cancer, consider asking:

1. What is my CA-125 level, and what does it mean for my specific situation?
2. Should HE4 or other markers be tested in my case?
3. Have I had BRCA1/2 and homologous recombination status testing? (This is important for treatment planning)
4. How will you use these biomarker results to monitor my response to treatment?
5. What biomarkers will you follow during my surveillance after treatment?

Key Takeaway

For early-stage ovarian cancer, CA-125 is the standard biomarker used alongside imaging and clinical assessment. While other markers may provide additional information in specific situations, the guidelines emphasize that biomarker testing works best as part of a complete clinical picture — not as a standalone tool. Molecular testing for BRCA and homologous recombination status is essential because it directly influences which treatments may be most effective for you.

According to NCCN Guidelines, "serum CA-125 levels correlate with extent of disease and may have prognostic value, so may help in treatment planning," but your oncologist will determine which specific tests are most appropriate for your individual case.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.